#byl719

[amcrasto]

FDA approves first PI3K inhibitor Piqray (alpelisib) for breast cancer

FDA approves first PI3K inhibitor Piqray (alpelisib) for breast cancer

FDA approves first PI3K inhibitor for breast cancer

syn https://newdrugapprovals.org/2018/06/25/alpelisib-byl-719/

Today, the U.S. Food and Drug Administration approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2…

View On WordPress

[amcrasto]

Alpelisib, BYL 719

Alpelisib (2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide PDT PAT WO 2010/029082 Chemical Names: Alpelisib; CAS 1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719 Molecular Formula: C19H22F3N5O2S Molecular Weight: 441.473 g/mol

alpelisib

1217486-61-7

BYL-719

BYL719

UNII-08W5N2C97Q

BYL 719

Alpelisib (BYL719)

View On WordPress